|
1
|
Harding AE and Thomas PK: The clinical
features of hereditary motor and sensory neuropathy types I and II.
Brain. 103:259–280. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inherited Peripheral Neuropathies Mutation
Database. http://www.molgen.ua.ac.be/CMTMutations/Home/IPN.cfm.
Accessed October 3, 2013
|
|
3
|
Züchner S and Vance JM: Molecular genetics
of autosomal-dominant axonal Charcot-Marie-Tooth disease.
Neuromolecular Med. 8:63–74. 2006.PubMed/NCBI
|
|
4
|
Züchner S, Mersiyanova IV, Muglia M, et
al: Mutations in the mitochondrial GTPase mitofusin 2 cause
Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 36:449–451.
2004.PubMed/NCBI
|
|
5
|
Nunnari J, Marshall WF, Straight A, Murray
A, Sedat JW and Walter P: Mitochondrial transmission during mating
in Saccharomyces cerevisiae is determined by mitochondrial
fusion and fission and the intramitochondrial segregation of
mitochondrial DNA. Mol Biol Cell. 8:1233–1242. 1997.PubMed/NCBI
|
|
6
|
Stenson PD, Mort M, Ball EV, et al: The
Human Gene Mutation Database: 2008 update. Genome Med. 1:132009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seeman P, Mazanec R, Zidar J, Hrusáková S,
Ctvrtecková M and Rautenstrauss B: Charcot-Marie-Tooth disease type
1A (CMT1A) and hereditary neuropathy with liability to pressure
palsies (HNPP): reliable detection of the CMT1A duplication and
HNPP deletion using 8 microsatellite markers in 2 multiplex PCRs.
Int J Mol Med. 6:421–426. 2000.
|
|
8
|
Ng PC and Henikoff S: Predicting
deleterious amino acid substitutions. Genome Res. 11:863–874. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sunyaev S, Ramensky V, Koch I, Lathe W
3rd, Kondrashov AS and Bork P: Prediction of deleterious human
alleles. Hum Mol Genet. 10:591–597. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
NHLBI Exome Sequencing Project (ESP).
Exome Variant Server (EVS). http://evs.gs.washington.edu/EVS.
Accessed October 3, 2013
|
|
11
|
Abecasis GR, Altshuler D, Auton A, et al;
1000 Genomes Project Consortium. A map of human genome variation
from population-scale sequencing. Nature. 467:1061–1073. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
1000 Genomes. http://www.1000genomes.org.
Accessed October 3, 2013
|
|
13
|
Sherry ST, Ward MH, Kholodov M, et al:
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res.
29:308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
National Center for Biotechnology
Information, National Library of Medicine. Database of Single
Nucleotide Polymorphisms (dbSNP). http://www.ncbi.nlm.nih.gov/SNP.
Accessed October 3, 2013
|
|
15
|
Verhoeven K, Claeys KG, Zuchner S, et al:
MFN2 mutation distribution and genotype/phenotype correlation in
Charcot-Marie-Tooth type 2. Brain. 129:2093–2102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casasnovas C, Banchs I, Cassereau J, et
al: Phenotypic spectrum of MFN2 mutations in the Spanish
population. J Med Genet. 47:249–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feely SM, Laura M, Siskind CE, et al: MFN2
mutations cause severe phenotypes in most patients with CMT2A.
Neurology. 76:1690–1696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chung KW, Kim SB, Park KD, et al: Early
onset severe and late-onset mild Charcot-Marie-Tooth disease with
mitofusin 2 (MFN2) mutations. Brain. 129:2103–2118. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cho HJ, Sung DH, Kim BJ and Ki CS:
Mitochondrial GTPase mitofusin 2 mutations in Korean patients with
Charcot-Marie-Tooth neuropathy type 2. Clin Genet. 71:267–272.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calvo J, Funalot B, Ouvrier RA, et al:
Genotype-phenotype correlations in Charcot-Marie-Tooth disease type
2 caused by mitofusin 2 mutations. Arch Neurol. 66:1511–1516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Züchner S, De Jonghe P, Jordanova A, et
al: Axonal neuropathy with optic atrophy is caused by mutations in
mitofusin 2. Ann Neurol. 59:276–281. 2006.PubMed/NCBI
|
|
22
|
Zhu D, Kennerson ML, Walizada G, Züchner
S, Vance JM and Nicholson GA: Charcot-Marie-Tooth with pyramidal
signs is genetically heterogeneous: families with and without MFN2
mutations. Neurology. 65:496–497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marchesi C, Ciano C, Salsano E, et al:
Co-occurrence of amyotrophic lateral sclerosis and
Charcot-Marie-Tooth disease type 2A in a patient with a novel
mutation in the mitofusin-2 gene. Neuromuscul Disord. 21:129–131.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loiseau D, Chevrollier A, Verny C, et al:
Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A
disease. Ann Neurol. 61:315–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Engelfried K, Vorgerd M, Hagedorn M, et
al: Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the
mitofusin 2 gene (MFN2). BMC Med Genet. 7:532006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nicholson GA, Magdelaine C, Zhu D, et al:
Severe early-onset axonal neuropathy with homozygous and compound
heterozygous MFN2 mutations. Neurology. 70:1678–1681. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Polke JM, Laurá M, Pareyson D, et al:
Recessive axonal Charcot-Marie-Tooth disease due to compound
heterozygous mitofusin 2 mutations. Neurology. 77:168–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lawson VH, Graham BV and Flanigan KM:
Clinical and electrophysiologic features of CMT2A with mutations in
the mitofusin 2 gene. Neurology. 65:197–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
